Novo Nordisk (NVO)
News
Profile
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - Other
Novo Nordisk manufactures and markets pharmaceutical products and services. Created in 1989 through a merger of two Danish companies dating back to the 1920s, it has become one of the world's leading companies in diabetes care, where Novo Nordisk pursues research into pulmonary delivery systems; other companies, such as Medtronic, have expanded into insulin pump systems. Novo Nordisk also commands large sectors of the markets in haemostasis management, growth hormone therapy and hormone replacement therapy. They are beginning research in the areas of autoimmune and chronic inflammatory diseases, using novel technologies such as translational immunology and monoclonal antibodies. With headquarters in Denmark, Novo Nordisk has international production facilities in seven countries, with affiliates or offices in 76 countries. Novo Nordisk employs approximately 29,000 people globally (as of Q4 2009), and markets its products in 179 countries. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Novo Nordisk has been ranked 25 among 100 Best companies to work for 2010 by Fortune.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Novo Nordisk is up 11.09% over the last year vs S&P 500 Total Return up 2.32%, Allergan up 10.15%, and Tianyin Pharmaceutical down 71.81%.
- NVO Total Returns
- ^SPXTR Total Returns
- AGN Total Returns
- TPI Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these NVO related companies
Pro Strategies Featuring NVO
Did Novo Nordisk make it into our Pro Portfolio Strategies?
NVO Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other NVO Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NVO | 135.80 | -2.83 | -2.04% | 80.41B |
| NVMI | 7.00 | +0.00 | +0.00% | 183.89M |
| NVLS | 42.29 | -1.21 | -2.78% | 3.080B |
| NVJ | 15.54 | -0.05 | -0.30% | |
| NVEC | 51.74 | -1.01 | -1.91% | 254.26M |
| NVE | 17.09 | -0.16 | -0.93% | 4.071B |
| NVDA | 12.54 | -0.18 | -1.42% | 7.857B |
| NVAX | 1.235 | -0.04 | -3.52% | 155.61M |
| NPK | 66.07 | -0.36 | -0.54% | 457.04M |
| NPF | 15.05 | -0.01 | -0.07% |
